Regional Analysis

Global High Content Screening Market- Regional Analysis

North America region held dominant position in the global high content screening (HCS) market in 2022 accounting for 43.7% share in terms of value, followed by Europe. According to data provided by Cente For Disease Control and Prevention on 8 May 2023, six out of ten Americans are now dealing with a chronic illness such as , heart disease, or every year.Due to important growth drivers such as increasing chronic disorders, North America held the highest share of the market.

European market trails with 20.1 % market share. According to data published by Eurostat on 17 April 2023, nearly one-fifth (18.2%) of healthcare spending in the EU in 2020 was for medical supplies, while more than half (53.1%) went towards curative and rehabilitative care. Eurostat is the statistical office of the European Union, responsible for publishing Europe-wide statistics and indicators that enable comparisons between countries and regions. By spending nearly two-fifths (37.4%) of total healthcare spending in the EU in 2020, hospitals were the top payers for healthcare services. This increase in healthcare infrastructure proves to be a major driver for a high European HCS market. The demand for clinical research is increasing again in the Asia Pacific region due to the lift in COVID-19 bans. State governments in India and China are adopting various research strategies for testing purposes. South Korea, Japan, and Singapore effectively tracked the COVID-19 virus through robust tracking systems , thus increasing a demand for HCS systems in the region.

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC Countries, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa